Clinical trial NCT03415906 (phase 2, status: withdrawn)
Conditions: heart failure
ICD codes: I50.814, I09.81, I50.82, I50.89, I50.9, T86.22, I11.0
Drugs: valsartan
SMILES: CCCCC(=O)N(CC1=CC=C(C=C1)C1=CC=CC=C1C1=NNN=N1)[C@@H](C(C)C)C(O)=O
Reason stopped: 
    difficulties in recruiting patients
  
Eligibility criteria:

        Inclusion Criteria:

          1. Women or men at the age ≥ 18 years, ≤ 80 years and able to give written informed
             consent

          2. Heart failure NYHA class II-III

          3. Ejection fraction of 40 % or less

          4. Stable dose of an ACE inhibitor or ARB over the last 4 weeks (A 2-day ACE inhibitor
             washout is scheduled before run-in; see Figure 3 on page 29.)

          5. Stable dose of a beta-blocker over the last 4 weeks unless contraindicated or not
             tolerated

          6. Patient has to be in sinus rhythm

          7. Patients capable of understanding the investigational nature, potential risks and
             benefits of the clinical trial

          8. Women without childbearing potential defined by:

               -  at least 6 weeks after surgical sterilization by bilateral tubal ligation or
                  bilateral oophorectomy or

               -  hysterectomy or uterine agenesis or

               -  ≥ 50 years and in postmenopausal state ≥ 1 year or

               -  < 50 years and in postmenopausal state ≥ 1 year with urine FSH > 40 IU/l and
                  urine estrogen < 30 ng/l or a negative estrogen test OR

             Women of childbearing potential with a negative urine ß-HCG pregnancy test at
             screening who agree to meet one of the following criteria from the time of screening,
             during the study and for a period of 7 days following the last administration of study
             medication:

               -  correct use of at least an acceptable effective contraceptive measure. The
                  following are deemed acceptable in this study: hormonal contraceptives (combined
                  oral contraceptives and estrogen-free pills with desogestrel, implants,
                  transdermal patches, hormonal vaginal devices or injections with prolonged
                  release), intrauterine device (IUS))

               -  true abstinence (periodic abstinence and withdrawal are not acceptable methods of
                  contraception)

               -  sexual relationship only with female partners and/or sterile male partners OR
                  Male

          9. Signed written informed consent and willingness to comply with treatment and follow-
             up procedures.

        Exclusion Criteria:

          1. History of hypersensitivity or allergy to any of the study drugs, drugs of similar
             chemical classes, ACE inhibitors (ACE-Is), ARBs, or neprilysin inhibitors, as well as
             known or suspected contraindications to the study drugs

          2. History of angioedema

          3. Recent acute decompensated heart failure within 2 months before screening

          4. Symptomatic hypotension and/or office systolic BP <110 mmHg at screening measured
             according to the recommendations of the European Society of Hypertension

          5. Combined intake of an ACE inhibitor and ARB over the last 4 weeks

          6. Estimated glomerular filtration rate (eGFR) <30 mL/min/1.73 m²

          7. Concomitant medication with Aliskiren in patients with Diabetes or patients with eGFR
             < 60 mL/min/1.73 m²

          8. Serum potassium >5.2 mmol/L at Visit 1 (screening)

          9. Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid, or other
             major cardiovascular surgery, PCI, or carotid angioplasty within the 3 months before
             screening

         10. History of heart transplant or on a transplant list or with LV assistance device

         11. History of severe pulmonary disease

         12. Documented untreated ventricular arrhythmia with syncopal episodes within the 3 months
             prior to Visit 1

         13. Presence of hemodynamically significant mitral and/or aortic valve disease/ left
             ventricular outflow tract obstruction, except mitral regurgitation secondary to LV
             dilatation

         14. Any surgical or medical condition which might significantly alter the absorption,
             distribution, metabolism, or excretion of study drugs

         15. Evidence of hepatic disease as determined by any one of the following: aspartate
             aminotransferase or alanine aminotransferase values exceeding 2× upper limit of normal
             at Visit 1, history of hepatic encephalopathy, history of esophageal varices, or
             history of porto-caval shunt

         16. Contraindications precluding microneurography measurements, such as relevant
             peripheral neuropathy as judged by the investigator

         17. Pregnancy or lactation period

         18. Current participation in any other clinical trial or participation in another clinical
             trial within 30 days before screening

         19. Known or suspected hypersensitivity to any of the active substances or any excipients
             of the investigational medicinal products

         20. Vulnerable subjects (i.e. persons under any administrative or legal supervision or
             persons kept in detention)